Developing First-in-Class therapies for cancer and AIIDs.
Cellestia is a clinical-stage biopharma led by an experienced team of scientists, drug developers and business professionals.
VISION
Cellestia is actively engaged in clinical development of first-in-class targeted therapeutics with untapped mode of action, to address unmet medical need in patients with oncology and immunological disorders.
MISSION
Develop CB-103, a novel, first-in-class, oral pan-NOTCH inhibitor with a unique mode of action for treatment of NOTCH dependent leukemias, lymphomas and solid tumors.
HISTORY
Cellestia Biotech AG was founded in 2014 as a spin-off from EPFL (Ecole Polytechnique Fédérale de Lausanne, Switzerland). Cellestia`s pipeline including lead candidate, oral small molecule CB-103 is based on proprietary know-how and more than two decade
